Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boston Scientific's score of 80 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Boston Scientific reported total greenhouse gas emissions of approximately 487,170,000 kg CO2e from Scope 1 and 2 combined. The breakdown includes 86,166,000 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 131,210,000 kg CO2e from Scope 2 emissions, with a market-based total of 25,825,000 kg CO2e. The company also disclosed significant Scope 3 emissions, totalling approximately 1,555,831,000 kg CO2e, which includes categories such as purchased goods and services, capital goods, and business travel. Boston Scientific has set ambitious climate commitments, pledging to achieve carbon neutrality in its manufacturing and key distribution sites by 2030. This commitment is part of a broader strategy to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2030, using 2019 as the base year. Additionally, the company aims for a 55% reduction in Scope 3 emissions per USD value added within the same timeframe. Long-term goals include a 97% reduction in Scope 1 and 2 emissions per USD value added, equivalent to a 90% absolute reduction by 2050. Boston Scientific is also committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050, as validated by the Science Based Targets initiative (SBTi). The company has already achieved a 68% reduction in Scope 1 and 2 emissions since 2009, demonstrating its commitment to sustainability and climate action.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boston Scientific is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.